OLD National Bancorp IN Acquires 1,043 Shares of Vericel Co. (NASDAQ:VCEL)

OLD National Bancorp IN grew its holdings in Vericel Co. (NASDAQ:VCEL) by 23.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,513 shares of the biotechnology company’s stock after acquiring an additional 1,043 shares during the quarter. OLD National Bancorp IN’s holdings in Vericel were worth $233,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. UniSuper Management Pty Ltd bought a new stake in shares of Vericel in the first quarter valued at about $595,000. BNP Paribas Financial Markets boosted its position in shares of Vericel by 99.7% in the first quarter. BNP Paribas Financial Markets now owns 111,760 shares of the biotechnology company’s stock valued at $5,814,000 after acquiring an additional 55,796 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its position in shares of Vericel by 10.9% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,021,695 shares of the biotechnology company’s stock valued at $53,149,000 after acquiring an additional 100,797 shares during the period. Silvercrest Asset Management Group LLC bought a new stake in shares of Vericel in the first quarter valued at about $6,538,000. Finally, Geneva Capital Management LLC boosted its position in shares of Vericel by 43.6% in the first quarter. Geneva Capital Management LLC now owns 679,165 shares of the biotechnology company’s stock valued at $35,330,000 after acquiring an additional 206,202 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity Group began coverage on shares of Vericel in a research report on Friday, August 9th. They issued a “buy” rating and a $57.00 target price for the company. StockNews.com downgraded Vericel from a “hold” rating to a “sell” rating in a research note on Tuesday, October 8th. BTIG Research dropped their price target on Vericel from $56.00 to $55.00 and set a “buy” rating for the company in a research note on Monday, July 15th. Canaccord Genuity Group began coverage on Vericel in a research note on Friday, August 9th. They issued a “buy” rating and a $57.00 price target for the company. Finally, Stephens boosted their price target on Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $57.71.

Insider Transactions at Vericel

In other news, CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total value of $724,150.00. Following the completion of the transaction, the chief executive officer now owns 220,937 shares of the company’s stock, valued at approximately $9,142,373.06. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Steven C. Gilman sold 5,833 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $41.36, for a total value of $241,252.88. Following the completion of the transaction, the director now owns 11,000 shares in the company, valued at $454,960. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Dominick Colangelo sold 17,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total transaction of $724,150.00. Following the completion of the transaction, the chief executive officer now owns 220,937 shares of the company’s stock, valued at approximately $9,142,373.06. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 29,166 shares of company stock valued at $1,200,764. 5.20% of the stock is currently owned by insiders.

Vericel Trading Up 1.1 %

VCEL stock opened at $42.28 on Thursday. The stock has a market capitalization of $2.05 billion, a P/E ratio of -4,228.00 and a beta of 1.67. Vericel Co. has a 12 month low of $32.28 and a 12 month high of $54.10. The firm has a 50-day moving average price of $45.03 and a 200-day moving average price of $46.51.

Vericel (NASDAQ:VCEL) last posted its earnings results on Thursday, August 1st. The biotechnology company reported ($0.10) EPS for the quarter, hitting analysts’ consensus estimates of ($0.10). The firm had revenue of $52.70 million during the quarter, compared to analysts’ expectations of $52.59 million. Vericel had a net margin of 0.37% and a return on equity of 0.35%. The business’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.11) earnings per share. As a group, equities analysts predict that Vericel Co. will post 0.12 EPS for the current fiscal year.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.